Bio‑Rad designs and sells laboratory analytical instruments, consumables, and related services used across research, clinical diagnostics, and bioprocessing. The company trades on the NYSE with a market capitalization around $10.4 billion and sits in the Life Science Tools & CDMO theme where scale and recurring consumable demand matter.
Quarterly revenue has run in a narrow band between about $585 million and $653 million over the past two years, with most quarters showing small year‑over‑year changes and no clear acceleration in top‑line growth. GAAP diluted EPS has been volatile, with large swings including deeply negative GAAP results in some quarters; GAAP EPS should be read as reported, not as adjusted operating EPS. The fundamentals picture is steady revenue generation but uneven GAAP profitability and no accelerating growth trend.
Technically and institutionally the stock reads as a leader within its group: institutional holders report about 91% ownership, accumulation and institutional scores are high, and the shares have outperformed the S&P by roughly 31% over three months and about 19% over 12 months. The price is in a constructive long‑term base, passing six of seven trend checks, but the pattern has not yet produced a verified breakout or an add setup.
Why now
Relative strength versus the S&P is strong (three‑month excess return +31.3%), institutional ownership is high (≈91%), and the trend checks are mostly positive, so the stock merits attention now as a potential theme leader once a verified breakout or EMA add setup appears.
The setup
Last close $376.41 sits above the 50‑day SMA ($350.74) and well above the 200‑day SMA ($304.59); the 9‑day EMA is $377.54 and the stock is roughly 0.3% below that short EMA. RSI is neutral at 55.5, 50/200 trend checks are mostly passed, and Weinstein classifies the stock in Stage 1 basing. EntryReadiness is “watch” and not actionable because there is no verified fresh breakout or 9/21‑day EMA add setup.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (5 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $9.48 (-4%) · FY'27E $10.03 (+6%) — 5 analysts
Risks
Revenue has been essentially flat year over year and revenue acceleration is absent, creating a growth risk if demand softens. GAAP diluted EPS has been highly volatile, including steep negative quarters, which raises earnings unpredictability and potential for future charges. Technically, the stock remains in a long‑term base without a confirmed breakout, so price can drift or correct before any sustainable uptrend begins.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%+19%✕
- AAnnual GAAP EPS growth ≥ 25%insufficient data—
- NNew highs — within 15% of 52-week high-3.57%✓
- SSupply/demand — up-day volume leads1.26x✓
- LLeader — outperforming the S&P 500+27% 6m✓
- IInstitutional sponsorshipmodel score 7/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Price remains below repeatedly tested long-term resistance, so the larger Stage 1 base is still intact.